$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio

$pbio Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223042131 Filed on November 20, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$312.4K	$413.0K	$144.0K
YoY Change	-48.56%	186.74%	-72.21%
Cost Of Revenue	$333.5K	$229.5K	$126.2K
YoY Change	-73.77%	81.82%	-51.12%
Gross Profit	-$21.17K	$183.5K	$17.83K
YoY Change	-96.81%	929.46%	-93.15%
Gross Profit Margin	-6.78%	44.44%	12.38%
Selling, General & Admin	$3.107M	$1.188M	$1.119M
YoY Change	393.21%	6.18%	-8.3%
% of Gross Profit		647.27%	6275.28%
Research & Development	$362.7K	$288.3K	$262.4K
YoY Change	43.45%	9.9%	-7.17%
% of Gross Profit		157.1%	1471.59%
Depreciation & Amortization	$28.11K	$24.34K	$5.780K
YoY Change	-45.73%	321.11%	-78.78%
% of Gross Profit		13.26%	32.42%
Operating Expenses	$3.470M	$1.476M	$1.381M
YoY Change	293.05%	6.89%	-8.09%
Operating Profit	-$3.491M	-$1.293M	-$1.363M
YoY Change	125.68%	-5.17%	9.72%
Interest Expense	-$1.485M	$4.339M	$2.034M
YoY Change	-62.66%	113.31%	-158.25%
% of Operating Profit
Other Income/Expense, Net	-$268.6K	-$4.337M	-$3.099M
YoY Change	-3169.49%	39.96%	-5211.13%
Pretax Income	-$9.904M	-$5.630M	-$4.462M
YoY Change	122.14%	26.17%	-9.87%
Income Tax
% Of Pretax Income
Net Earnings	-$10.54M	-$5.630M	-$4.462M
YoY Change	115.45%	26.17%	-9.87%
Net Earnings / Revenue	-3373.1%	-1363.18%	-3098.09%
Basic Earnings Per Share		-$0.29	-$0.44
Diluted Earnings Per Share	-$0.33	-$0.29	-$400.9K
COMMON SHARES
Basic Shares Outstanding	21.73M shares	17.76M shares	9.074M shares
Diluted Shares Outstanding		21.72M shares	11.13M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$81.28K	$5.260K	$230.9K
YoY Change	2000.26%	-97.72%	-65.21%
Cash & Equivalents	$81.28K	$5.263K	$230.9K
Short-Term Investments
Other Short-Term Assets	$222.6K	$219.3K	$218.5K
YoY Change	-13.55%	0.37%	-64.82%
Inventory	$304.9K	$467.2K	$1.387M
Prepaid Expenses
Receivables	$151.2K	$329.3K	$166.3K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$760.1K	$1.021M	$2.002M
YoY Change	-38.86%	-49.01%	-23.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$84.93K	$91.41K	$111.9K
YoY Change	-17.82%	-18.3%	-36.3%
Goodwill
YoY Change
Intangibles	$0.00	$252.4K	$360.6K
YoY Change	-100.0%	-30.0%
Long-Term Investments	$61.88K	$77.92K	$51.93K
YoY Change	-2.77%	50.05%	-53.86%
Other Assets
YoY Change
Total Long-Term Assets	$289.6K	$581.2K	$838.0K
YoY Change	-62.21%	-30.65%	17.41%
TOTAL ASSETS
Total Short-Term Assets	$760.1K	$1.021M	$2.002M
Total Long-Term Assets	$289.6K	$581.2K	$838.0K
Total Assets	$1.050M	$1.602M	$2.840M
YoY Change	-47.77%	-43.59%	-14.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.320M	$1.063M	$608.1K
YoY Change	107.21%	74.75%	45.46%
Accrued Expenses	$3.119M	$3.166M	$2.800M
YoY Change	11.11%	13.08%	25.23%
Deferred Revenue
YoY Change
Short-Term Debt	$22.60M	$20.90M	$18.83M
YoY Change	12.43%	11.0%	46.32%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$33.58M	$29.96M	$32.29M
YoY Change	-2.41%	-7.23%	42.42%
LONG-TERM LIABILITIES
Long-Term Debt	$161.9K	$162.5K	$150.0K
YoY Change	7.91%	8.35%	-71.54%
Other Long-Term Liabilities	$65.52K	$81.93K	$171.9K
YoY Change	-53.78%	-52.34%	55.4%
Total Long-Term Liabilities	$227.4K	$244.5K	$321.9K
YoY Change	-22.06%	-24.06%	-49.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$33.58M	$29.96M	$32.29M
Total Long-Term Liabilities	$227.4K	$244.5K	$321.9K
Total Liabilities	$33.80M	$30.20M	$32.62M
YoY Change	-2.57%	-7.4%	39.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$169.0M	-$158.5M	-$128.9M
YoY Change	26.3%	22.92%
Common Stock	$353.7K	$234.0K	$122.2K
YoY Change	158.48%	91.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$32.75M	-$28.60M	-$29.78M
YoY Change
Total Liabilities & Shareholders Equity	$1.050M	$1.602M	$2.840M
YoY Change	-47.77%	-43.59%	-14.8%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$10.54M	-$5.630M	-$4.462M
YoY Change	115.45%	26.17%	-9.87%
Depreciation, Depletion And Amortization	$28.11K	$24.34K	$5.780K
YoY Change	-45.73%	321.11%	-78.78%
Cash From Operating Activities	-$1.132M	-$733.8K	-$1.053M
YoY Change	-20.65%	-30.32%	-47.17%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$7.500K	-$15.86K
YoY Change	-100.0%	-147.29%	2837.04%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$7.500K	-$15.86K
YoY Change	-100.0%	-52.71%	2837.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.208M	712.7K	1.178M
YoY Change	0.7%	-39.51%	-54.87%
NET CHANGE
Cash From Operating Activities	-1.132M	-733.8K	-1.053M
Cash From Investing Activities	0.000	-7.500K	-15.86K
Cash From Financing Activities	1.208M	712.7K	1.178M
Net Change In Cash	76.01K	-28.60K	109.3K
YoY Change	-133.48%	-126.16%	-82.28%
FREE CASH FLOW
Cash From Operating Activities	-$1.132M	-$733.8K	-$1.053M
Capital Expenditures	$0.00	$7.500K	-$15.86K
Free Cash Flow	-$1.132M	-$741.3K	-$1.037M
YoY Change	-20.65%	-28.53%	-47.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0000830656
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductAndServiceOtherMember
CY2022Q3	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductAndServiceOtherMember
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductAndServiceOtherMember
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductAndServiceOtherMember
CY2023Q3	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities		usd
CY2023Q3	PBIO	Deemed Dividends On Extension Of Warrants DeemedDividendsOnExtensionOfWarrants		usd
CY2022Q3	PBIO	Deemed Dividends On Extension Of Warrants DeemedDividendsOnExtensionOfWarrants		usd
	PBIO	Deemed Dividends On Extension Of Warrants DeemedDividendsOnExtensionOfWarrants		usd
	PBIO	Loss On Extinguishment Of Accrued Liabilities And Debt LossOnExtinguishmentOfAccruedLiabilitiesAndDebt		usd
	PBIO	Common Stock And Warrants Issued For Debt Extension CommonStockAndWarrantsIssuedForDebtExtension		usd
	PBIO	Preferred Stock Issued For Debt Extension PreferredStockIssuedForDebtExtension		usd
	PBIO	Preferred Stock Issued For Services PreferredStockIssuedForServices		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	PBIO	Early Asu202006 Adoption EarlyAsu202006Adoption		usd
	PBIO	Discount From Warrants Issued With Debt DiscountFromWarrantsIssuedWithDebt		usd
	PBIO	Preferred Stock Issued With Debt PreferredStockIssuedWithDebt		usd
	PBIO	Conversion Of Debt Accrued Interest And Accrued Dividend For Preferred Stock ConversionOfDebtAccruedInterestAndAccruedDividendForPreferredStock		usd
	PBIO	Conversion Of Common Stock For Preferred Stock ConversionOfCommonStockForPreferredStock		usd
	PBIO	Extension Of Warrants For Series Aa Preferred Stock ExtensionOfWarrantsForSeriesAaPreferredStock		usd
CY2023Q1	PBIO	Stock Issued During Period Value Conversion Of Convertible Securities Conversion Of Preferred Stock For Common Stock StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock		usd
CY2023Q2	PBIO	Extension Of Warrants For Series Aa Preferred Stock ExtensionOfWarrantsForSeriesAaPreferredStock		usd
CY2023Q2	PBIO	Stock Issued During Period Value Conversion Of Convertible Securities Conversion Of Preferred Stock For Common Stock StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock		usd
CY2023Q2	PBIO	Stock Issued During Period Value Conversion Of Common Stock To Preferred Stock StockIssuedDuringPeriodValueConversionOfCommonStockToPreferredStock		usd
CY2023Q3	PBIO	Stock Issued During Period Value Conversion Of Convertible Securities Conversion Of Preferred Stock For Common Stock StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock		usd
CY2022Q2	PBIO	Stock Issued During Period Value Conversion Of Convertible Securities Conversion Of Preferred Stock For Common Stock StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock		usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount		usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent		usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38185
	dei	Entity Registrant Name EntityRegistrantName	PRESSURE BIOSCIENCES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	MA
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-2652826
	dei	Entity Address Address Line1 EntityAddressAddressLine1	14 Norfolk Avenue
	dei	Entity Address City Or Town EntityAddressCityOrTown	South Easton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02375
	dei	City Area Code CityAreaCode	(508)
	dei	Local Phone Number LocalPhoneNumber	230-1828
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21726433	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5263	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3865	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	329263	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	295374	usd
CY2023Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	905759	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	982973	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	467155	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	686383	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	219283	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	257527	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	1020964	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1243149	usd
CY2023Q3	us-gaap	Equity Method Investments EquityMethodInvestments	77918	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	63638	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	91409	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	103351	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	159424	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	282095	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	252404	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	317308	usd
CY2023Q3	us-gaap	Assets Assets	1602119	usd
CY2022Q4	us-gaap	Assets Assets	2009541	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1062565	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	637238	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	376760	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	167247	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2722666	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2497762	usd
CY2023Q3	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	4576350	usd
CY2022Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	10803983	usd
CY2023Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	253152	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	58242	usd
CY2023Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	18222120	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	17823669	usd
CY2023Q3	PBIO	Other Debt Unamortized Discounts Net OtherDebtUnamortizedDiscountsNet	0	usd
CY2022Q4	PBIO	Other Debt Unamortized Discounts Net OtherDebtUnamortizedDiscountsNet	0	usd
CY2023Q3	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	2030510	usd
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1638969	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	647986	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	634885	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	66259	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	142171	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	29958368	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34404166	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	162522	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	150000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	71287	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	139924	usd
CY2023Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	10645	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1822	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	244454	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	291746	usd
CY2023Q3	us-gaap	Liabilities Liabilities	30202822	usd
CY2022Q4	us-gaap	Liabilities Liabilities	34695912	usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	100	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1098	usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	100	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1098	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23399945	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23399945	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13682910	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13682910	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	234000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	136829	usd
CY2023Q3	PBIO	Warrants To Acquire Common Stock WarrantsToAcquireCommonStock	35684321	usd
CY2022Q4	PBIO	Warrants To Acquire Common Stock WarrantsToAcquireCommonStock	31995762	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	93973646	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	69006145	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-158492770	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133826205	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-28600703	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-32686371	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1602119	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2009541	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	413009	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	144032	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1665412	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1122169	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	413009	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	144032	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1665412	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1122169	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	229457	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	126203	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	844684	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	742707	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	288345	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	262370	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1004437	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	716685	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	157773	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	226526	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	537802	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	422422	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1030243	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	892293	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5290564	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2591644	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	1705818	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	1507392	usd
	us-gaap	Costs And Expenses CostsAndExpenses	7677487	usd
	us-gaap	Costs And Expenses CostsAndExpenses	4473458	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1292809	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1363360	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6012075	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3351289	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	4338759	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	2034021	usd
	us-gaap	Interest Expense InterestExpense	14112098	usd
	us-gaap	Interest Expense InterestExpense	6448771	usd
CY2023Q3	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-5965	usd
CY2022Q3	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-8675	usd
	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	14280	usd
	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-8047	usd
CY2022Q3	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities	-1054122	usd
	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities	687591	usd
	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities	-1809249	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7588	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2059	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11820	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-904	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4337136	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3098877	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13398407	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8266971	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5629945	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4462237	usd
	us-gaap	Net Income Loss NetIncomeLoss	-19410482	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11618260	usd
	PBIO	Deemed Dividends On Extension Of Warrants DeemedDividendsOnExtensionOfWarrants	3626950	usd
CY2023Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	632054	usd
CY2022Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	431709	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1629133	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1295566	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6261999	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4893946	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24666565	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12913826	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.24
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.24
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21716950	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21716950	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11131742	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11131742	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20337229	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20337229	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10429817	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10429817	shares
	us-gaap	Net Income Loss NetIncomeLoss	-19410482	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11618260	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	687591	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	10000	usd
	PBIO	Noncash Lease Expense NoncashLeaseExpense	122671	usd
	PBIO	Noncash Lease Expense NoncashLeaseExpense	82001	usd
	PBIO	Common Stock And Warrants Issued For Interest CommonStockAndWarrantsIssuedForInterest	3715204	usd
	PBIO	Common Stock And Warrants Issued For Interest CommonStockAndWarrantsIssuedForInterest	2196278	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	84341	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	67985	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-3213622	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1777863	usd
	PBIO	Loss On Extinguishment Of Accrued Liabilities And Debt LossOnExtinguishmentOfAccruedLiabilitiesAndDebt	1809249	usd
	PBIO	Common Stock And Warrants Issued For Debt Extension CommonStockAndWarrantsIssuedForDebtExtension	-1671573	usd
	PBIO	Preferred Stock Issued For Debt Extension PreferredStockIssuedForDebtExtension	2683600	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1706420	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	128984	usd
	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	14280	usd
	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	-8047	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1978645	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	367370	usd
	PBIO	Preferred Stock Issued For Services PreferredStockIssuedForServices	617200	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	33889	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11568	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-219228	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	238973	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-38244	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-204141	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	425327	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	80130	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	209513	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	104258	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-144549	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-82001	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1551380	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2083239	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2053823	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3051257	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7495	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20754	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7495	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20754	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	150000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	81111	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17443	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4336665	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3428249	usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	2043681	usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	1815000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	159186	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	762500	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	2462269	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1086946	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	159000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	259600	usd
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	2086658	usd
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	1506066	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2062716	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3170580	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1398	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	98569	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3865	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	132311	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5263	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	230880	usd
	us-gaap	Interest Paid Net InterestPaidNet	1219038	usd
	us-gaap	Interest Paid Net InterestPaidNet	938451	usd
	PBIO	Early Asu202006 Adoption EarlyAsu202006Adoption	473027	usd
	us-gaap	Stock Issued1 StockIssued1	1293270	usd
	us-gaap	Stock Issued1 StockIssued1	512593	usd
	PBIO	Discount From Warrants Issued With Debt DiscountFromWarrantsIssuedWithDebt	93576	usd
	PBIO	Common Stock Issued In Lieu Of Cash For Dividend CommonStockIssuedInLieuOfCashForDividend	162528	usd
	PBIO	Common Stock Issued In Lieu Of Cash For Dividend CommonStockIssuedInLieuOfCashForDividend	306333	usd
	PBIO	Preferred Stock Issued With Debt PreferredStockIssuedWithDebt	539487	usd
	PBIO	Noncash Preferred Stock Dividends NoncashPreferredStockDividends	1629133	usd
	PBIO	Noncash Preferred Stock Dividends NoncashPreferredStockDividends	1295566	usd
	PBIO	Conversion Of Preferred Stock For Common Stock ConversionOfPreferredStockForCommonStock	14869	usd
	PBIO	Conversion Of Preferred Stock For Common Stock ConversionOfPreferredStockForCommonStock	44	usd
	PBIO	Conversion Of Debt Accrued Interest And Accrued Dividend For Preferred Stock ConversionOfDebtAccruedInterestAndAccruedDividendForPreferredStock	10017212	usd
	PBIO	Conversion Of Debt Into Common Stock ConversionOfDebtIntoCommonStock	509033	usd
	PBIO	Conversion Of Debt Into Common Stock ConversionOfDebtIntoCommonStock	350500	usd
	PBIO	Conversion Of Common Stock For Preferred Stock ConversionOfCommonStockForPreferredStock	6240	usd
	PBIO	Extension Of Warrants For Series Aa Preferred Stock ExtensionOfWarrantsForSeriesAaPreferredStock	3626950	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-32686371	usd
CY2022Q1	PBIO	Warrants Issued For Debt Extension WarrantsIssuedForDebtExtension	132537	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	472900	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	81111	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1430244	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	431807	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1419335	usd
CY2023Q1	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	61609	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	509033	usd
CY2023Q1	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	102435	usd
CY2023Q1	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	1705234	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1029939	usd
CY2023Q1	PBIO	Stock Issued With Debt StockIssuedWithDebt	1087751	usd
CY2023Q1	PBIO	Sale Of Common Stock For Cash SaleOfCommonStockForCash	100000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6857834	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-32449321	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	565272	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	135554	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	172400	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	491634	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	10017212	usd
CY2023Q2	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	60093	usd
CY2023Q2	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	1296446	usd
CY2023Q2	PBIO	Stock Issued With Debt StockIssuedWithDebt	156674	usd
CY2023Q2	PBIO	Sale Of Common Stock For Cash SaleOfCommonStockForCash	50000	usd
CY2023Q2	PBIO	Stock Issued During Period Value Issued Preferred Stock For Services StockIssuedDuringPeriodValueIssuedPreferredStockForServices	505700	usd
CY2023Q2	PBIO	Stock Issued During Period Value Issuance Of Preferred Stock For Debt Extension StockIssuedDuringPeriodValueIssuanceOfPreferredStockForDebtExtension	1397000	usd
CY2023Q2	PBIO	Preferred Stock Issued For Debt Settlement PreferredStockIssuedForDebtSettlement	539487	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6922703	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-25115096	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	140622	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	632054	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	325301	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	150000	usd
CY2023Q3	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	713524	usd
CY2023Q3	PBIO	Stock Issued With Debt StockIssuedWithDebt	48845	usd
CY2023Q3	PBIO	Stock Issued During Period Value Issued Preferred Stock For Services StockIssuedDuringPeriodValueIssuedPreferredStockForServices	111500	usd
CY2023Q3	PBIO	Stock Issued During Period Value Issuance Of Preferred Stock For Debt Extension StockIssuedDuringPeriodValueIssuanceOfPreferredStockForDebtExtension	1286600	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5629945	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-28600703	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-22208961	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-22208961	usd
CY2022Q1	PBIO	Cumulative Effect Period Of Adoption Adjustment CumulativeEffectPeriodOfAdoptionAdjustment	-473027	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	64483	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	432149	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	77700	usd
CY2022Q1	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	39761	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	350500	usd
CY2022Q1	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	64256	usd
CY2022Q1	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	1173458	usd
CY2022Q1	PBIO	Stock Issued With Debt StockIssuedWithDebt	142480	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	87436	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4239685	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-24748311	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32074	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17443	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	431708	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	67800	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	191303	usd
CY2022Q2	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	151021	usd
CY2022Q2	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	388515	usd
CY2022Q2	PBIO	Stock Issued With Debt StockIssuedWithDebt	35848	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2916338	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-27212353	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32427	usd
CY2022Q3	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	634305	usd
CY2022Q3	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	91056	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	167375	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	431709	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1050475	usd
CY2022Q3	PBIO	Stock Issued During Period Value Warrants Issued For Services StockIssuedDuringPeriodValueWarrantsIssuedForServices	14734	usd
CY2022Q3	PBIO	Stock Issued With Debt StockIssuedWithDebt	334265	usd
CY2022Q3	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	6140	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4462237	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-29775522	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-29775522	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zYraWLwCbbDc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zm5R37SknlC9">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2728243	usd
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2255216	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	413000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	144000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1665000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1122000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	413000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	144000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1665000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1122000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	413000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	144000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1665000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1122000	usd
CY2023Q3	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	329000	usd
CY2022Q4	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	295000	usd
CY2023Q3	us-gaap	Deferred Revenue DeferredRevenue	59000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	60000	usd
CY2023Q3	PBIO	Extended Warranty Service ExtendedWarrantyService	59000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zMl2RlXnukI7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zZTiEoNRkMLd">Concentrations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Credit Risk</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--FairValueConcentrationOfRiskTextBlock_zXPtacHaIwJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September 30, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B9_zACmltS78MG6" style="display: none">Schedule of Customer Concentration Risk Percentage</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Top five customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zeOV2M2NpGd9" style="width: 11%; text-align: right" title="Concentration credit risk percentage">80</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zQs8EYL9nSg6" style="width: 11%; text-align: right" title="Concentration credit risk percentage">42</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9qY1ynSdOyc" style="width: 11%; text-align: right" title="Concentration credit risk percentage">49</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z3wUAEHD9Ail" style="width: 11%; text-align: right" title="Concentration credit risk percentage">31</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Federal agencies</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfbfUmA1sia5" style="text-align: right" title="Concentration credit risk percentage">18</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znLYxRJ430eh" style="text-align: right" title="Concentration credit risk percentage">4</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztBRvAsF3lSb" style="text-align: right" title="Concentration credit risk percentage">5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUK4GDfjvYZi" style="text-align: right" title="Concentration credit risk percentage">1</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2023 and December 31, 2022. The Top Five Customers category may include federal agency receivable balances if applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,<br/> 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Top five customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGVAFETEZyde" style="width: 16%; text-align: right" title="Concentration credit risk percentage">80</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbIgSLLagjAi" style="width: 16%; text-align: right" title="Concentration credit risk percentage">93</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Federal agencies</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFxDHad8RHV2" style="text-align: right" title="Concentration credit risk percentage">22</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAoa40X5b2Q2" style="text-align: right" title="Concentration credit risk percentage">0</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A4_zyn5ewVgcUDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Share Based Compensation ShareBasedCompensation	1706420	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	128984	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6261999	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4893946	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24666565	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12913826	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21716950	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21716950	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11131742	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11131742	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20337229	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20337229	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10429817	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10429817	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.24
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.24
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	47768850	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33217416	shares
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	140622	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	32427	usd
CY2023Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
	us-gaap	Debt Instrument Convertible Conversion Price Increase DebtInstrumentConvertibleConversionPriceIncrease	2.50
CY2023Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
	us-gaap	Debt Instrument Convertible Conversion Price Increase DebtInstrumentConvertibleConversionPriceIncrease	2.50
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	140622	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	32427	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1706420	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	128984	usd
CY2023Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	77918	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	63638	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	15887	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	64393	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	66969	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	51778	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	199027	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	61481	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	137546	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	122671	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	82001	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M2D
CY2023Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
	us-gaap	Debt Instrument Convertible Conversion Price Decrease DebtInstrumentConvertibleConversionPriceDecrease	2.50
CY2023Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
	us-gaap	Debt Instrument Convertible Conversion Price Increase DebtInstrumentConvertibleConversionPriceIncrease	2.50
CY2023Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q3	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	1	usd
CY2023Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	159424	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	282095	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	66259	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	142171	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	71287	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	139924	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	137546	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	282095	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
	us-gaap	Operating Lease Cost OperatingLeaseCost	153290	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	152193	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	110205	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	123514	usd
	us-gaap	Lease Cost LeaseCost	263495	usd
	us-gaap	Lease Cost LeaseCost	275707	usd
CY2023Q3	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	648470	usd
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	2462269	usd
	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	July 2020 to September 2024
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	12300000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	18279186	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	744393	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	455517	usd
CY2023Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	18222120	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	17823669	usd
	us-gaap	Debt Instrument Convertible Stock Price Trigger DebtInstrumentConvertibleStockPriceTrigger	2.50
CY2023Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
	PBIO	Debt Default Convertible Conversion Ratio DebtDefaultConvertibleConversionRatio	0.75	pure
	us-gaap	Debt Instrument Convertible Stock Price Trigger DebtInstrumentConvertibleStockPriceTrigger	2.50
	PBIO	Debt Default Convertible Conversion Ratio DebtDefaultConvertibleConversionRatio	0.75	pure
CY2023Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q3	PBIO	Percentage Of Price Rate PercentageOfPriceRate	0.10	pure
CY2023Q3	PBIO	Convertible Lesser Per Share ConvertibleLesserPerShare	2.5
CY2023Q3	PBIO	Convertible Lesser Discount Percent ConvertibleLesserDiscountPercent	0.25	pure
	us-gaap	Debt Conversion Original Debt Interest Rate Of Debt DebtConversionOriginalDebtInterestRateOfDebt	0.35	pure
CY2023Q3	PBIO	Convertible Lesser Per Share ConvertibleLesserPerShare	2.50
CY2023Q3	PBIO	Convertible Lesser Discount Percent ConvertibleLesserDiscountPercent	0.25	pure
	us-gaap	Debt Instrument Convertible Threshold Trading Days DebtInstrumentConvertibleThresholdTradingDays	5	integer
CY2023Q3	us-gaap	Other Long Term Debt OtherLongTermDebt	2193032	usd
CY2022Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	1788969	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	162522	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	150000	usd
CY2023Q3	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	2030510	usd
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1638969	usd
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-05-02
CY2023Q3	PBIO	Non Convertible Debt Instrument Amount NonConvertibleDebtInstrumentAmount	861500	usd
CY2023Q3	us-gaap	Notes Payable NotesPayable	150000	usd
CY2023Q3	PBIO	Accrued Interest Rate Percent AccruedInterestRatePercent	0.0375	pure
	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	731	usd
	PBIO	Deferred Interest DeferredInterest	14719	usd
	us-gaap	Principal Transactions Revenue PrincipalTransactionsRevenue	2197	usd
CY2023Q3	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	100	usd
CY2022Q4	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	1098	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17586591	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	17570591	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2330484	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	117552	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	645829	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19153694	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	18289721	shares

Files In Submission

Name	View Source	Status
pbio-20230930_cal.xml	Edgar Link	unprocessable
0001493152-23-042131-index-headers.html	Edgar Link	pending
0001493152-23-042131-index.html	Edgar Link	pending
0001493152-23-042131.txt	Edgar Link	pending
0001493152-23-042131-xbrl.zip	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex21-1_001.jpg	Edgar Link	pending
ex21-1_002.jpg	Edgar Link	pending
ex21-1_003.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pbio-20230930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
pbio-20230930_def.xml	Edgar Link	unprocessable
pbio-20230930_pre.xml	Edgar Link	unprocessable
pbio-20230930_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio

2023 Q4 Form 10-Q Financial Statement

#000149315223042131 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBIO PRESSURE BIOSCIENCES INC Stock $pbio

2023 Q4 Form 10-Q Financial Statement

#000149315223042131 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio